{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:19:30Z","timestamp":1793103570313,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T00:00:00Z","timestamp":1661644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study examines changes in utilization and costs trends associated with migraine medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Migraine attacks are a burden to many patients. There are many pharmacotherapy options available with newer migraine drug classes entering the market in the past decade. Little is known about the use, associated costs, and the impact of the newer agents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective, cross-sectional study examined 2017\u20132020 administrative claims from a large national pharmacy benefits manager. Patients aged\u2009\u2265\u200918\u00a0years enrolled in commercial, Medicare, Medicaid, or health insurance exchange insurance plans who filled\u2009\u2265\u20092 prescription claims for triptans, ergotamines, isometheptenes, gepants, ditans, and CGRP mABs were included. A two-sample t-test was conducted to estimate whether differences in mean utilization and costs between 2017 and 2020 were statistically significant for migraine drug classes, except for CGRP mABs, which were estimated between 2018 and 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The sample ranged from 161,369 (2017) to 240,330 (2020) patients. 84.5% (<jats:italic>n<\/jats:italic>\u2009=\u2009203,110; 2020) of patients were women. The number of 30-day adjusted prescription fills for prophylaxis remained stable over the four-year period, except for CGRP mABs, which increased from 0.5% (<jats:italic>n<\/jats:italic>\u2009=\u20090.007; 2018) to 5.3% (<jats:italic>n<\/jats:italic>\u2009=\u20090.075; 2020). Antiepileptics, antidepressants and beta blockers were the most common prophylaxes, while triptans, non-steroidal anti-inflammatory drugs\/non-narcotic analgesics and opioids were the most common treatments utilized. CGRP mABs were the most expensive, while utilization of triptans were the highest. CGRP mABs had the largest increase in utilization (177.5%) and costs (166.3%) PPPM in 2020 ($291.17) compared to 2018 ($109.35), the year they were first available (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Between 2018 and 2020, costs increased overall and for commercial and Medicare enrollees, but remained unchanged for Medicaid and HIX members.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study demonstrates a shift in migraine medication utilization from 2017\u20132020, where increased use of CGRP mABs had a significant contribution to increased costs. These increased pharmacy costs must be weighed against the improved tolerability of these agents likely resulting in other healthcare and indirect cost savings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01476-y","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T07:02:32Z","timestamp":1661670152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Trends in utilization and costs of migraine medications, 2017\u20132020"],"prefix":"10.1186","volume":"23","author":[{"given":"Jennifer L.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiraat","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Peasah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C. S.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monal","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester B.","family":"Good","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,28]]},"reference":[{"issue":"4","key":"1476_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/head.13281","volume":"58","author":"R Burch","year":"2018","unstructured":"Burch R, Rizzoli P, Loder E (2018) The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache J Head Face Pain 58(4):496\u2013505. https:\/\/doi.org\/10.1111\/head.13281","journal-title":"Headache J Head Face Pain"},{"issue":"1","key":"1476_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23(1):34. https:\/\/doi.org\/10.1186\/s10194-022-01402-2","journal-title":"J Headache Pain"},{"issue":"S1","key":"1476_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.13301","volume":"58","author":"R Agosti","year":"2018","unstructured":"Agosti R (2018) Migraine burden of disease: from the patient\u2019s experience to a socio-economic view. Headache J Head Face Pain 58(S1):17\u201332. https:\/\/doi.org\/10.1111\/head.13301","journal-title":"Headache J Head Face Pain"},{"issue":"1","key":"1476_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain 20(1):41. https:\/\/doi.org\/10.1186\/s10194-019-0993-0","journal-title":"J Headache Pain"},{"issue":"5","key":"1476_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343\u2013349. https:\/\/doi.org\/10.1212\/01.wnl.0000252808.97649.21","journal-title":"Neurology"},{"issue":"1","key":"1476_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) on behalf of lifting the burden: the global campaign against headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain."},{"issue":"4","key":"1476_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37(4):631\u2013649. https:\/\/doi.org\/10.1016\/j.ncl.2019.06.001","journal-title":"Neurol Clin"},{"issue":"1","key":"1476_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jns.2014.11.004","volume":"348","author":"A Raggi","year":"2015","unstructured":"Raggi A, Schiavolin S, Leonardi M et al (2015) Chronic migraine with medication overuse: Association between disability and quality of life measures, and impact of disease on patients\u2019 lives. J Neurol Sci 348(1):60\u201366. https:\/\/doi.org\/10.1016\/j.jns.2014.11.004","journal-title":"J Neurol Sci"},{"issue":"1","key":"1476_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1526-4610.2011.02046.x","volume":"52","author":"D Buse","year":"2012","unstructured":"Buse D, Manack A, Serrano D et al (2012) Headache impact of chronic and episodic migraine: results from the American migraine prevalence and prevention study. Headache J Head Face Pain 52(1):3\u201317. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02046.x","journal-title":"Headache J Head Face Pain"},{"issue":"1","key":"1476_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H et al (2021) Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain 22(1):29. https:\/\/doi.org\/10.1186\/s10194-021-01243-5","journal-title":"J Headache Pain"},{"issue":"7","key":"1476_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/head.13829","volume":"60","author":"SN Gibbs","year":"2020","unstructured":"Gibbs SN, Shah S, Deshpande CG et al (2020) United States patients\u2019 perspective of living with migraine: country-specific results from the global \u201cmy migraine voice\u201d survey. Headache 60(7):1351\u20131364. https:\/\/doi.org\/10.1111\/head.13829","journal-title":"Headache"},{"issue":"10","key":"1476_CR12","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.18553\/jmcp.2020.20100","volume":"26","author":"DC Buse","year":"2020","unstructured":"Buse DC, Yugrakh MS, Lee LK, Bell J, Cohen JM, Lipton RB (2020) Burden of illness among people with migraine and \u2265 4 monthly headache days while using acute and\/or preventive prescription medications for migraine. J Manag Care Spec Pharm 26(10):1334\u20131343. https:\/\/doi.org\/10.18553\/jmcp.2020.20100","journal-title":"J Manag Care Spec Pharm"},{"key":"1476_CR13","doi-asserted-by":"publisher","unstructured":"Baigi K, Stewart WF. Chapter 25 - Headache and migraine: a leading cause of absenteeism. In: Lotti M, Bleecker ML, eds. Handbook of Clinical Neurology. Vol 131. Occupational Neurology. Elsevier; 2015:447\u2013463 https:\/\/doi.org\/10.1016\/B978-0-444-62627-1.00025-1","DOI":"10.1016\/B978-0-444-62627-1.00025-1"},{"issue":"8","key":"1476_CR14","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML et al (2019) Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache J Head Face Pain 59(8):1286\u20131299. https:\/\/doi.org\/10.1111\/head.13613","journal-title":"Headache J Head Face Pain"},{"issue":"1","key":"1476_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11916-013-0385-0","volume":"18","author":"M Lanteri-Minet","year":"2014","unstructured":"Lanteri-Minet M (2014) Economic burden and costs of chronic migraine. Curr Pain Headache Rep 18(1):385. https:\/\/doi.org\/10.1007\/s11916-013-0385-0","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"1476_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10194-017-0756-8","volume":"18","author":"J Kim","year":"2017","unstructured":"Kim J, Cho SJ, Kim WJ, Yang KI, Yun CH, Chu MK (2017) Insufficient sleep is prevalent among migraineurs: a population-based study. J Headache Pain 18(1):50. https:\/\/doi.org\/10.1186\/s10194-017-0756-8","journal-title":"J Headache Pain"},{"issue":"9","key":"1476_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11916-017-0641-9","volume":"21","author":"CP Yang","year":"2017","unstructured":"Yang CP, Wang SJ (2017) Sleep in patients with chronic migraine. Curr Pain Headache Rep 21(9):39. https:\/\/doi.org\/10.1007\/s11916-017-0641-9","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"1476_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10194-018-0887-6","volume":"19","author":"TJ Song","year":"2018","unstructured":"Song TJ, Cho SJ, Kim WJ, Yang KI, Yun CH, Chu MK (2018) Poor sleep quality in migraine and probable migraine: a population study. J Headache Pain 19(1):58. https:\/\/doi.org\/10.1186\/s10194-018-0887-6","journal-title":"J Headache Pain"},{"issue":"6","key":"1476_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","volume":"28","author":"A Negro","year":"2019","unstructured":"Negro A, Martelletti P (2019) Gepants for the treatment of migraine. Expert Opin Investig Drugs 28(6):555\u2013567. https:\/\/doi.org\/10.1080\/13543784.2019.1618830","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"1476_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1741-7015-7-71","volume":"7","author":"T Sprenger","year":"2009","unstructured":"Sprenger T, Goadsby PJ (2009) Migraine pathogenesis and state of pharmacological treatment options. BMC Med 7(1):71. https:\/\/doi.org\/10.1186\/1741-7015-7-71","journal-title":"BMC Med"},{"key":"1476_CR21","unstructured":"Golden L. Peters P. Migraine Overview and Summary of Current and Emerging Treatment Options. Am J Manag Care. 2019;25(2). https:\/\/www.ajmc.com\/view\/migraine-overview-and-summary--of-current-and-emerging-treatment-options Accessed 25 Jan, 2022."},{"key":"1476_CR22","doi-asserted-by":"publisher","unstructured":"Scuteri D, Adornetto A, Rombol\u00e0 L, et al. New Trends in Migraine Pharmacology: Targeting Calcitonin Gene\u2013Related Peptide (CGRP) With Monoclonal Antibodies. Front Pharmacol. 2019;10. https:\/\/www.frontiersin.org\/article\/https:\/\/doi.org\/10.3389\/fphar.2019.00363. Accessed 19 Jan. , 2022","DOI":"10.3389\/fphar.2019.00363"},{"issue":"1","key":"1476_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s10194-019-0974-3","volume":"20","author":"TP Do","year":"2019","unstructured":"Do TP, Guo S, Ashina M (2019) Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain 20(1):37. https:\/\/doi.org\/10.1186\/s10194-019-0974-3","journal-title":"J Headache Pain"},{"issue":"9","key":"1476_CR24","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/head.13661","volume":"59","author":"CEJ Ceriani","year":"2019","unstructured":"Ceriani CEJ, Wilhour DA, Silberstein SD (2019) Novel medications for the treatment of migraine. Headache J Head Face Pain 59(9):1597\u20131608. https:\/\/doi.org\/10.1111\/head.13661","journal-title":"Headache J Head Face Pain"},{"issue":"1","key":"1476_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","volume":"20","author":"EC Agostoni","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P et al (2019) Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain 20(1):92. https:\/\/doi.org\/10.1186\/s10194-019-1038-4","journal-title":"J Headache Pain"},{"issue":"5","key":"1476_CR26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/head.13275","volume":"58","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P (2018) Direct and Indirect healthcare resource utilization and costs among migraine patients in the United States. Headache J Head Face Pain 58(5):700\u2013714. https:\/\/doi.org\/10.1111\/head.13275","journal-title":"Headache J Head Face Pain"},{"key":"1476_CR27","unstructured":"Guttentag S. The Yearly Cost of Preventing and Treating Migraine. GoodRx. Published February 9, 2021. https:\/\/www.goodrx.com\/conditions\/migraine\/yearly-cost-preventing-treating-migraine Accessed 28 Dec, 2021."},{"key":"1476_CR28","doi-asserted-by":"crossref","unstructured":"Tsou A, Rouse B, Bloshichak A, Treadwell J. Drugs and devices for migraine prevention: interactive evidence maps. Patient-Centered Outcomes Research Insititute; 2021:95.","DOI":"10.25302\/EMV1.2021.2"},{"issue":"10","key":"1476_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.15585\/mmwr.mm6610a1","volume":"66","author":"A Shah","year":"2017","unstructured":"Shah A, Hayes CJ, Martin BC (2017) Characteristics of Initial prescription episodes and likelihood of long-term opioid use - United States, 2006\u20132015. MMWR Morb Mortal Wkly Rep 66(10):265\u2013269. https:\/\/doi.org\/10.15585\/mmwr.mm6610a1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"1476_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia Int J Headache 37(5):470\u2013485. https:\/\/doi.org\/10.1177\/0333102416678382","journal-title":"Cephalalgia Int J Headache"},{"issue":"2","key":"1476_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40261-020-00997-1","volume":"41","author":"DK Ha","year":"2021","unstructured":"Ha DK, Kim MJ, Han N, Kwak JH, Baek IH (2021) Comparative efficacy of oral calcitonin-gene-related peptide antagonists for the treatment of acute migraine: Updated meta-analysis. Clin Drug Investig 41(2):119\u2013132. https:\/\/doi.org\/10.1007\/s40261-020-00997-1","journal-title":"Clin Drug Investig"},{"key":"1476_CR32","unstructured":"LeClair J, Ostroff J, Ostroff M. An Overview of Generic Triptans for Migraine. US Pharm. 2017;42(6 (Generic Drugs suppl)):14\u201318."},{"issue":"S3","key":"1476_CR33","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/head.13379","volume":"58","author":"SJ Tepper","year":"2018","unstructured":"Tepper SJ (2018) History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache J Head Face Pain 58(S3):238\u2013275. https:\/\/doi.org\/10.1111\/head.13379","journal-title":"Headache J Head Face Pain"},{"key":"1476_CR34","unstructured":"Lehmann, Christine. The CGRP Antagonists Are Here. Now How Do You Use Them?: The Real-World Experience of Migraine Experts. NeurologyToday. Published January 10, 2019. https:\/\/journals.lww.com\/neurotodayonline\/fulltext\/2019\/01100\/the_cgrp_antagonists_are_here__now_how_do_you_use.1.aspx?casa_token=EgsQ7EIrx50AAAAA:3iZgbxuA7OUb_SnzuYKd14fFEJufqpamalDybNWc5kDY9F31In6feiYAL6I3S-g20cYXJezfBxOY76wua1sQqca6 Accessed 26 April, 2022."},{"issue":"1","key":"1476_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.12499","volume":"55","author":"MJ Marmura","year":"2015","unstructured":"Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 55(1):3\u201320. https:\/\/doi.org\/10.1111\/head.12499","journal-title":"Headache"},{"issue":"10","key":"1476_CR36","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.neurol.2020.04.027","volume":"176","author":"J Schoenen","year":"2020","unstructured":"Schoenen J, Manise M, Nonis R, G\u00e9rard P, Timmermans G (2020) Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention. Rev Neurol (Paris) 176(10):788\u2013803. https:\/\/doi.org\/10.1016\/j.neurol.2020.04.027","journal-title":"Rev Neurol (Paris)"},{"issue":"12","key":"1476_CR37","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1097\/JOM.0000000000001450","volume":"60","author":"AM Gilligan","year":"2018","unstructured":"Gilligan AM, Foster SA, Sainski-Nguyen A, Sedgley R, Smith D, Morrow P (2018) Direct and Indirect costs among United States commercially insured employees with Migraine. J Occup Environ Med 60(12):1120\u20131127. https:\/\/doi.org\/10.1097\/JOM.0000000000001450","journal-title":"J Occup Environ Med"},{"issue":"1","key":"1476_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s10194-020-01185-4","volume":"21","author":"ML Sumelahti","year":"2020","unstructured":"Sumelahti ML, Sumanen M, Sumanen MS et al (2020) My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland. J Headache Pain 21(1):118. https:\/\/doi.org\/10.1186\/s10194-020-01185-4","journal-title":"J Headache Pain"},{"issue":"1","key":"1476_CR39","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/13696998.2021.1925557","volume":"24","author":"P Martelletti","year":"2021","unstructured":"Martelletti P, Schwedt TJ, Vo P et al (2021) Healthcare resource use and indirect costs associated with migraine in Italy: results from the My Migraine Voice survey. J Med Econ 24(1):717\u2013726. https:\/\/doi.org\/10.1080\/13696998.2021.1925557","journal-title":"J Med Econ"},{"issue":"1","key":"1476_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-022-01448-2","volume":"23","author":"P Irimia","year":"2022","unstructured":"Irimia P, Garc\u00eda-Azor\u00edn D, N\u00fa\u00f1ez M et al (2022) Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study. J Headache Pain 23(1):78. https:\/\/doi.org\/10.1186\/s10194-022-01448-2","journal-title":"J Headache Pain"},{"key":"1476_CR41","unstructured":"U.S. Census Bureau. Health Insurance Coverage in the United States: 2019. U.S. Department of Commerce; 2020. https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2020\/demo\/p60-271.pdf Accessed 6 Jan, 2022."}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01476-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T07:02:38Z","timestamp":1661670158000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01476-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,28]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01476-y","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,28]]},"assertion":[{"value":"12 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}